Yaqiang HUANG

Yaqiang HUANG


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2015 in BMC Urology
Verified
Journal Article
Open access
PDF file
YZYan-Ru Zeng
Yan-Ru Zeng
ZHZhaodong Han
Zhaodong Han
CWCong Wang
Cong Wang
CCChao Cai
Chao Cai
YHYaqiang HUANG
Yaqiang HUANG
WZWeide Zhong
Weide Zhong
The NIMA-related kinase 2 (NEK2) is a serine/threonine kinase that is involved in regulation of centrosome duplication and spindle assembly during mitosis. Dysregulation of these processes causes chromosome instability and aneuploidy, which are hallmark changes of many solid tumors. However, whether aberrant expression of NEK2 is associated with outcome of prostate cancer (PCa) patients remains to be determined. Expression of NEK2 in human PCa cells and primary PCa tissues was assessed by quantitative RT-PCR. Expression of NEK2 in human PCa cells was depleted with siRNA. Effects of the depletion on cell proliferation, survival, and tumorigenicity were assessed both in vitro with cell cultures and in vivo with subcutaneous implantation of xenografts. In silico analyses of the online Taylor dataset were carried out to determine whether the expression level of NEK2 correlated with the clinicopathological characteristics of prostate cancer. Compared with benign human prostatic epithelial cells and tissues, the expression of NEK2 was elevated in human PCa cells and primary PCa tissues. Depleting NEK2 expression inhibited human PCa cell proliferation in vitro and xenograft growth in vivo. Expression level of NEK2 in PCa positively correlated with the Gleason score and pathologic stage of the patient. The results suggest that overexpression of NEK2 has the potential to serve as a biomarker for PCa prognosis. Further validation with large sample pool is warrant.


27 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WWWeiyang Wei
Weiyang Wei
CZChuanpeng Zhou
Chuanpeng Zhou
HYHao Yang
Hao Yang
QWQi Wang
Qi Wang
HHHongxing Huang
Hongxing Huang
YHYaqiang HUANG
Yaqiang HUANG
To compare the clinical efficacy and safety of mini-percutaneous nephrolithotomy (MPCNL) and standard percutaneous nephrolithotomy (SPCNL) in the treatment of kidney stones combine with renal insufficiency. The data of 320 patients with renal calculi and an eGFR < 60 mL/min/1.73m2 who underwent percutaneous nephrolithotomy (PCNL) at Zhongshan City People’s Hospital from January 2018 to June 2023 were retrospectively analyzed; 164 patients were treated with MPCNL, and 156 were treated with SPCNL. The clinical efficacy of the MPCNL and SPCNL regimens was compared in terms of stone-free rate (SFR), renal function change, hemoglobin (HGB) drop and other complication rates (complications were classified by using the Clavien‒Dindo system). The SFR was 67.1% in the MPCNL group and 67.9% in the SPCNL group (P = 0.867). The overall eGFR of the two groups was significantly improved at 1 month after the operation (P < 0.001). Postoperative renal function was stable, improved and worse in 50.0% (n = 82) vs. 53.8% (n = 84), 39.0% (n = 64) vs. 42.4% (n = 66) and 11.0% (n = 18) vs. 3.8% (n = 6) of the MPCNL and SPCNL patients, respectively, compared with preoperative renal function (P = 0.053). In addition, the overall postoperative complication rates between the two groups was not significantly different (P = 0.103). Patients who underwent MPCNL had a lower transfusion rate (7.9% vs. 16.7%, P = 0.017) and shorter hospital stay (4.57 ± 3.14 vs. 7.16 ± 4.05 days, P < 0.001) than those in the SPCNL group. MPCNL and SPCNL have positive effects on the treatment of renal calculi in patients with renal insufficiency; both have acceptable SFRs and complication rates, stable or improved renal function in most patients.

22 March 2024 in Heliyon
Verified
Journal Article
Open access
YHYi Huang
Yi Huang
LLLibo Liu
Libo Liu
QGQinghua Gan
Qinghua Gan
ZSZefeng Shen
Zefeng Shen
YYYuhui Yao
Yuhui Yao
XFXinxiang Fan
Xinxiang Fan
The prognostic significance of tumor size with adrenocortical carcinoma (ACC) patients has not yet been thoroughly evaluated. Our objective was to investigate the influence of tumor size on prognostic value in adult ACC patients. The Surveillance, Epidemiology and End Results Program (SEER) was employed to identify adult ACC patients who had been diagnosed from 2004 to 2015. The “X-Tile” program determined the optimal cutoff value of tumor size. Cancer-specific survival (CSS) and overall survive (OS) were estimated. The survival outcomes and risk factors were analyzed by the Kaplan-Meier methods and the multivariable cox regression respectively. A total 426 adult ACC patients were included. Univariable and multivariable cox analysis revealed age, larger tumor size and metastasis as consistent predictors of lower CSS and OS. The optimal cutoff value of tumor size was identified as 8.5 cm using X-tile software, and Kaplan-Meier method showed dramatic prognostic difference between patients with larger tumors (>8.5 cm) and smaller tumors (≤8.5 cm) (log-rank test, P < 0.001). Subgroup analyses revealed no statistical significance and a consistent proportionate effect of tumor size on CSS and OS across all eight pre-specified subgroups. Interestingly, an additional subgroup analysis showed that ACC patients could not benefit from chemotherapy in terms of CSS and OS. The study suggests that tumor size is a crucial prognostic factor in ACC patients and a cutoff value 8.5 cm might indicate a poor outcome. Given the limitations of the available data, it is challenging to conclusively determine the benefit of chemotherapy in adult ACC patients across different tumor size ranges.

15 October 2025 in BMC Urology
Verified
Journal Article
Open access
PDF file
WQWang Qi
Wang Qi
LQLin Qisheng
Lin Qisheng
WWWei Weiyang
Wei Weiyang
LYLiu Yuan
Liu Yuan
LLLi Linfeng
Li Linfeng
YHYaqiang HUANG
Yaqiang HUANG
Bladder cancer (BC) is the ninth most prevalent cancer globally, with approximately 75% of cases classified as non-muscle-invasive bladder cancer (NMIBC). Although transurethral resection of bladder tumor (TURBT) is the standard treatment for NMIBC, there remains a considerable risk of postoperative residual tumors. Accurately identifying patients who require repeat transurethral resection of bladder tumor (Re-TURBT) remains a significant clinical challenge. Magnetic resonance imaging (MRI) exhibits high accuracy in detecting residual tumors after TURBT, aiding clinical decision-making. However, its relatively low specificity limits its clinical applicability. Urinary methylation markers, particularly those associated with H4 cluster protein 6 (H4C6) and Twist Family BHLH Transcription Factor 1 (TWIST1), have demonstrated high sensitivity and specificity in detecting bladder cancer, showing promising clinical performance. The combined detection of H4C6 and TWIST1 gene methylation provides a more reliable method for identifying residual tumors post-TURBT. Integrating the VI-RADS score with urine gene methylation analysis could complement each other, improving the accuracy of residual tumor detection and enhancing clinical applicability. This study aimed to evaluate the predictive value of clinical/pathological factors, urinary H4C6 and TWIST1 gene methylation, and their combined performance in identifying postoperative residual tumors in NMIBC patients. Morning urine samples from NMIBC patients at Zhongshan City People’s Hospital (June 2022–August 2024) were analyzed for H4C6 and TWIST1 methylation levels. Patients underwent MRI and Re-TURBT. Logistic regression was used to identify predictors of residual tumors, and a nomogram was developed. Model performance was evaluated using Receiver Operating Characteristic (ROC) curves and decision curve analysis (DCA). Among the 55 patients included in the study, the area under the ROC curve (AUC) for urinary H4C6 methylation was 0.698, whereas TWIST1 methylation had an AUC of 0.758. Combined dual-gene methylation yielded an AUC of 0.764. The AUC for VI-RADS scoring was 0.888. When dual-gene methylation and hematuria were combined with VI-RADS scores, the prediction model achieved an AUC of 0.972. DCA demonstrated that the prediction model offers substantial clinical benefit across a broad range of threshold probabilities. The combined prediction model of dual-gene methylation, hematuria, and VI-RADS scores offers a powerful non-invasive method to assist clinicians in identifying high-risk patients with residual tumors after TURBT, thereby reducing unnecessary Re-TURBT and improving patient management. Urinary H4C6 and TWIST1 gene methylation, along with VI-RADS scoring, show high diagnostic performance in predicting residual tumors following TURBT in NMIBC patients. A combined prediction model incorporating dual-gene methylation, hematuria, and VI-RADS scores achieves superior discrimination, excellent calibration, and strong clinical utility.

14 April 2026 in BMC Medical Imaging
Verified
Journal Article
Open access
PDF file
JKJianqiu Kong
Jianqiu Kong
YHYi Huang
Yi Huang
YXYichun Xing
Yichun Xing
SFShuogui Fang
Shuogui Fang
KTKaiwen Tan
Kaiwen Tan
XFXinxiang Fan
Xinxiang Fan
Bladder cancer (BCa) prognostication is pivotal for tailored clinical interventions. Using machine learning, this study assesses prognostic capabilities of H&E-stained BCa images. From 569 slides across The Cancer Genome Atlas, Sun Yat-sen Memorial Hospital, and Zhongshan City People’s Hospital, we extracted 150 histopathological markers each. LASSO regression yielded a pathomic fingerprint, which was further validated. An integrated model, fusing this fingerprint with salient clinicopathological indicators, displayed notable efficacy in both training (C-index: 0.658) and validation cohorts (C-index: 0.590–0.597). Incorporating the fingerprint, age, and N stage, the model excelled in training (C-index: 0.703) and validations (C-index: 0.612–0.646). Decision curve analysis underscored its clinical relevance. Conclusively, our pathomic-clinical framework offers advanced precision in BCa patient prognosis, enhancing clinical decision-making.